Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 5
1987 8
1988 18
1989 17
1990 24
1991 24
1992 28
1993 28
1994 39
1995 36
1996 37
1997 42
1998 37
1999 52
2000 58
2001 62
2002 82
2003 89
2004 92
2005 89
2006 88
2007 69
2008 56
2009 65
2010 54
2011 56
2012 34
2013 65
2014 65
2015 52
2016 56
2017 64
2018 55
2019 55
2020 74
2021 60
2022 49
2023 43
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

1,810 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for claritin
Search for claritine instead (3 results)
Loratadine.
AlMasoud N, Bakheit AH, Alshammari MFM, Abdel-Aziz HA, AlRabiah H. AlMasoud N, et al. Profiles Drug Subst Excip Relat Methodol. 2022;47:55-90. doi: 10.1016/bs.podrm.2021.10.002. Epub 2021 Dec 7. Profiles Drug Subst Excip Relat Methodol. 2022. PMID: 35396016 Review.
This chapter discusses, by a critical extensive review of the literature, the description of loratadine in terms of its names, formulae, elemental composition, appearance, methods of preparation. The profile contains physicochemical properties of Loratadine, includi …
This chapter discusses, by a critical extensive review of the literature, the description of loratadine in terms of its names, formul …
H1-antihistamines for chronic spontaneous urticaria.
Sharma M, Bennett C, Cohen SN, Carter B. Sharma M, et al. Cochrane Database Syst Rev. 2014 Nov 14;2014(11):CD006137. doi: 10.1002/14651858.CD006137.pub2. Cochrane Database Syst Rev. 2014. PMID: 25397904 Free PMC article. Review.
For this same outcome, comparison of desloratadine versus placebo in the intermediate term (5 mg) (RR 37.00, 95% CI 2.31 to 593.70) and in the short term (20 mg) (RR 15.97, 95% CI 1.04 to 245.04)favoured desloratadine, but no differences were seen between 5 mg and 10 mg for short …
For this same outcome, comparison of desloratadine versus placebo in the intermediate term (5 mg) (RR 37.00, 95% CI 2.31 to 593.70) and in t …
EDITORIAL.
Kennedy DW. Kennedy DW. Int Forum Allergy Rhinol. 2015 Dec;5(12):1083-4. doi: 10.1002/alr.21692. Int Forum Allergy Rhinol. 2015. PMID: 26769189 No abstract available.
FDA approves OTC Claritin.
[No authors listed] [No authors listed] FDA Consum. 2003 Jan-Feb;37(1):3. FDA Consum. 2003. PMID: 12625285 Free article. No abstract available.
Reply.
Trautmann A, Stoevesandt J. Trautmann A, et al. J Allergy Clin Immunol Pract. 2017 Mar-Apr;5(2):535-536. doi: 10.1016/j.jaip.2016.12.020. J Allergy Clin Immunol Pract. 2017. PMID: 28283170 No abstract available.
Shiitake dermatitis.
Bachmeyer C, Rouff E. Bachmeyer C, et al. CMAJ. 2017 Mar 20;189(11):E439. doi: 10.1503/cmaj.160644. CMAJ. 2017. PMID: 28385716 Free PMC article. No abstract available.
Desloratadine.
McClellan K, Jarvis B. McClellan K, et al. Drugs. 2001;61(6):789-96; discussion 797. doi: 10.2165/00003495-200161060-00007. Drugs. 2001. PMID: 11398910
Desloratadine is the orally active major metabolite of the nonsedating H1-antihistamine loratadine. The drug had no adverse cardiovascular effects in various animal models or when administered at 9 times the recommended adult dosage for 10 days in volunteers. ...
Desloratadine is the orally active major metabolite of the nonsedating H1-antihistamine loratadine. The drug had no adverse cardiovas …
Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis.
Kaiser HB, Banov CH, Berkowitz RR, Bernstein DI, Bronsky EA, Georgitis JW, Mendelson LM, Rooklin AR, Sholler LJ, Stricker WW, Harrison JE, Danzig MR, Lorber RR. Kaiser HB, et al. Am J Ther. 1998 Jul;5(4):245-51. doi: 10.1097/00045391-199807000-00007. Am J Ther. 1998. PMID: 10099066 Clinical Trial.
In this double-blind, placebo-controlled, multicenter study, 469 patients with moderate-to-severe SAR symptoms were treated for 2 weeks with one of the following: Claritin-D 24 Hour (a combination tablet formulation of loratadine 10 mg in the coating and pseudoephed …
In this double-blind, placebo-controlled, multicenter study, 469 patients with moderate-to-severe SAR symptoms were treated for 2 weeks with …
1,810 results